期刊文献+

三维适形放疗联合S-1治疗局部晚期胰腺癌临床观察 被引量:8

Effect of three dimensional-conformal radiotherapy combined with S-1 to treat locally advanced pancreatic cancer
下载PDF
导出
摘要 目的:探讨三维适形放疗联合S-1治疗局部晚期胰腺癌的临床疗效。方法:36例患者随机分为放化疗组与单纯放疗组。放疗组给予5个三维适形放疗野等中心照射,剂量为50Gy/(25f·5w),放化疗组患者的放疗射野及剂量同放疗组,同时自放疗的第一天起口服S-1,剂量60mg/m2,2次/d,第1至28天,休14天重复,每例患者接受2周期S-1化疗。观察疗效及不良反应。结果:放化疗组有效率高于单放组(66.7%vs44.4%),放化疗组1年生存率高于单放组(45%vs 20%),不良反应放化疗组稍高于单放组,患者可以耐受。结论:三维适形放疗联合S-1是局部晚期胰腺癌较为理想的方法,疗效优于单纯放疗组。 Objective:To study the effect of three dimensional - conformal radiotherapy combined with S - 1 in treating locally advanced pancreatic cancer. Methods :All 36 patients with locally advanced pancreatic cancer were divided into 2 groups, 18 patients received three dimensional -conformal radiotherapy combined with S -1,18 patients received only three dimensional - conformal radiotherapy. Radiotherapy was delivered by 6MV - X ray. Elected sinergy clinic accerator,5 coplanar radiation fields was made by Xio 3 - D three dimensional treat planning system. Concurrent chemoradiotherapy was given at the first day S - 1 60mg/d 1 - 28 of 42 - day cycle, at least two cycles. Results: The overall effective rate was 66.7% of chemo -radiotherapy. The 1 -year survival rate was 45%. Conclusion :The dimensional - eonformal radiotherapy combined with S - 1 had higher effective rate and 1 - year survival rate than on- ly radiotherapy to treat locally advanced pancreatic cancer.
出处 《现代肿瘤医学》 CAS 2014年第1期129-131,共3页 Journal of Modern Oncology
关键词 胰腺癌 化学治疗 三维适形放疗 pancreatic carcinoma chemotherapy three dimensional - conformal radiotherapy
  • 相关文献

参考文献7

二级参考文献54

  • 1李艳丽,苏学峰,李南征,柴海燕,王鹤皋.常规分割立体定向适形放射治疗晚期胰腺癌28例临床观察[J].中国肿瘤临床,2004,31(13):747-748. 被引量:3
  • 2黄建琴,刘鲁明.吉西他滨在胰腺癌治疗中的应用[J].世界临床药物,2006,27(8):476-479. 被引量:1
  • 3张洪波,陈龙华,吴德华,曹小飞.局部晚期胰腺癌的三维适形放疗结合动脉灌注化疗疗效及预后多因素分析[J].广东医学,2007,28(3):412-414. 被引量:3
  • 4Wesolowski R, Lee C, Kim R. Is there a role for second - line chemotherapy in adavanced gastric cancer [ J ] ? Lancet Oncol, 2009,10:903 - 912.
  • 5Maehara Y. S - 1 in gastric cancer: a comprehensive review [ J]. Gastric Cancer,2003,6 ( Suppl 1 ) :2 - 8.
  • 6M Jin, H Lu, J Li, et al. Ramdomized 3 - armed phase Ⅲ study of S - 1 monotherapy versus S - 1/CDDP(SP) versus 5 - FU/CDDP (FP) in paitents(pts) with advanced gastric cancer( AGC ) : SC - 101 study[J]. J Clin Oneol,26(suppl):4533.
  • 7N Boku, S Yamamoto, K Shirao, et al. Randomized phase Ⅲ study of 5 -fluorouracil (5 - FU) alone versus combination of irinotecan and cisplatin(CP) versus S- 1 alone in advanced gastric cancer (JCOG9912) [J]. J Clin Ocol,2007,25:18.
  • 8Koizumi W, Tanabe S, Saigenji K, et al. GotohM : Phase Ⅰ / Ⅱ study of S1 combined with cisplatin in patients with advanced gastric cancer[ J]. Br Cancer,2003,89:2207.
  • 9Wasaburo K, Hiroyuki N, Takuo H, et al. S1 plus cisplatin versus S1 alone for first - line treatment of advanced gastric cancer( SPIR- ITS trial) :a phase Ⅲ trial [J]. Lancet 0ncol,2008,9(3) :215 - 221.
  • 10Takai S,Satoi S,Yanagimoto H,et al.Neoadjuvant chemoradiation in patients with potentially resectable pancreatic cancer[J].Pancreas,2008,36:26-30.

共引文献231

同被引文献55

引证文献8

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部